[PDF][PDF] Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme
DA Reardon, KL Fink, T Mikkelsen… - Journal of clinical …, 2008 - researchgate.net
Journal of clinical oncology, 2008•researchgate.net
Purpose Cilengitide, an inhibitor of v3 and v5 integrin receptors, demonstrated minimal
toxicity and durable activity across a wide range of doses administered to adults with
recurrent glioblastoma multiforme (GBM) in a prior phase I study. The current multicenter
phase II study was conducted to evaluate the activity and safety of cilengitide in GBM
patients at first recurrence.
toxicity and durable activity across a wide range of doses administered to adults with
recurrent glioblastoma multiforme (GBM) in a prior phase I study. The current multicenter
phase II study was conducted to evaluate the activity and safety of cilengitide in GBM
patients at first recurrence.
Purpose
Cilengitide, an inhibitor of v3 and v5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma multiforme (GBM) in a prior phase I study. The current multicenter phase II study was conducted to evaluate the activity and safety of cilengitide in GBM patients at first recurrence.
researchgate.net